PageSourceSearch

https://opentargets.org/news

html opentargets.org collected 2026-10-01 09:17:10 UTC 38,595 bytes, 1,013 lines download raw bytes

1<!DOCTYPE html>
2<html lang="en-GB">
3  <head>
4    
5      <!-- Google Tag Manager -->
6      
6<script>
vendor: 368 bytes, lines 6-11
6
7        (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
8        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
9        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
10        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
11        })(window,document,'script','dataLayer','
11GTM-P66K3L6
vendor: 10 bytes, lines 11-12
11');
12      
12</script>
12
13    <!-- End Google Tag Manager -->
14    
15    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
16    <meta charset="utf-8">
17    <title>News - Open Targets</title>
18    <meta name="description" content="Open Targets is a public-private initiative to generate evidence on the validity of therapeutic targets based on genome-scale experiments and analysis.">
19    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0/css/bootstrap.min.css" integrity="sha384-Gn5384xqQ1aoWXA+058RXPxPg6fy4IWvTNh0E263XmFcJlSAwiGgFAW/dAiS6JXm" crossorigin="anonymous">
20    <link rel="stylesheet" href="/assets/css/main.css">
21    <link rel="shortcut icon" href="/assets/img/favicons/open-targets-favicon.png" type="image/png" />
22    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.7.2/css/all.min.css">
23  </head>
24  <body>
25    
26      <!-- Google Tag Manager (noscript) -->
vendor: 74 bytes, lines 26-27
26
27      <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=
27GTM-P66K3L6
vendor: 102 bytes, lines 27-30
27"
28        height="0" width="0" style="display:none;visibility:hidden"></iframe>
29      </noscript>
30    
30<!-- End Google Tag Manager (noscript) -->
31    
32    <nav class="navbar navbar-expand-lg navbar-light bg-white">
33  <div class="container">
34    <a class="navbar-brand" href="/">
35      <img src="/assets/img/ten-years-logo-colour.png" style="width:150px" alt="Ten year anniversary logo, Open Targets helix logo and wordmark">
36    </a>
37    <button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarResponsive" aria-controls="navbarResponsive" aria-expanded="false" aria-label="Toggle navigation">
38      <span class="navbar-toggler-icon"></span>
39    </button>
40    <div class="collapse navbar-collapse" id="navbarResponsive">
41      <ul class="navbar-nav ml-auto">
42        <li class="nav-item dropdown">
43          <a class="nav-link dropdown-toggle" href="#" id="navbarDropdownMenuLink" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">
44            About
45          </a>
46          <div class="dropdown-menu" aria-labelledby="navbarDropdownMenuLink">
47            <a class="dropdown-item" href="/partners">Partners</a>
48            <a class="dropdown-item" href="/people">Team</a>
49            <a class="dropdown-item" href="/history">History</a>
50            <a class="dropdown-item" href="/branding">Branding</a>
51          </div>
52        </li>
53        <li class="nav-item dropdown">
54          <a class="nav-link dropdown-toggle" href="#" id="navbarDropdownMenuLink" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">
55            Research
56          </a>
57          <div class="dropdown-menu" aria-labelledby="navbarDropdownMenuLink">
58            <a class="dropdown-item" href="/science">Science overview</a>
59            <a class="dropdown-item" href="/publications">Publications</a>
60          </div>
61        </li>
62        <li class="nav-item">
63          <a class="nav-link" href="/news">News</a>
64        </li>
65        <li class="nav-item">
66          <a class="nav-link" href="/jobs">Jobs</a>
67        </li>
68        <li class="nav-item">
69          <a class="nav-link" href="https://blog.opentargets.org/" target="_blank">Blog</a>
70        </li>
71        <li class="nav-item">
72          <a class="nav-link" href="/contact">Contact</a>
73        </li>
74      </ul>
75    </div>
76  </div>
77</nav>
78  
79
80    <header class="page-header bg-blue">
81  <div class="container">
82    <div class="row">
83      <div class="col-sm-12 text-center text-white">
84        <h1>News</h1>
85      </div>
86    </div>
87  </div>
88</header>
89
90<section class="py-5 my-5">
91  <div class="container">
92    <div class="row">
93      
94        
95          <div class="row">
96            <div class="col-lg-12">
97              <div class="row">
98                <div class="col-lg-6">
99  
100  <a href="/" target="_blank">
101    <img src="/assets/img/masld-trajectory-july26.png" class="img-fluid" alt="Graphic highlighting the liver in the human body, overlayed with data from the publication showing the established human MASLD trajectory based on patient transcriptomic data."/>
102  </a>
103  
104</div>
105<div class="col-lg-6">
106  <h4>Molecular map of liver disease could transform how MASLD is diagnosed and monitored</h4>
107  <p class="mt-3">
108    14 July 2026
109  </p>
110  <p>
111    <p><strong>A new study establishes a molecular map of disease progression in Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD), and identifies a set of blood biomarkers that could improve diagnosis.</strong></p>
112
113<h3 id="summary">Summary</h3>
114
115<ul>
116  <li>Scientists mapped the molecular progression of MASLD, uncovering how biological processes driving liver damage change over time, creating a framework for more precise stage-specific therapies.</li>
117  <li>They identified a blood... 
118  </p>
119  
120  <p class="card-title">
121    <a href="/news/masld-trajectory-14-july-26.html" class="btn btn-primary">Read more</a>
122  </p>
123  
124
125</div>  
126              </div>
127            </div>
128            <div class="col-lg-12">
129              <hr class="my-5" />
130            </div>
131          </div>
132        
133          <div class="row">
134            <div class="col-lg-12">
135              <div class="row">
136                <div class="col-lg-6">
137  
138  <a href="/" target="_blank">
139    <img src="/assets/img/krzak-ibdverse.png" class="img-fluid" alt="UMAP of the data from the project"/>
140  </a>
141  
142</div>
143<div class="col-lg-6">
144  <h4>Cellular study maps gene activity changes across more than 50 gut cell types in Crohn’s disease</h4>
145  <p class="mt-3">
146    15 June 2026
147  </p>
148  <p>
149    <p>The latest IBDverse study identifies the genes expressed in Crohn’s disease, reveal
149ing a lasting ‘molecular scar’ in the gut lining.</p>
150
151<p>A detailed cellular study of Crohn’s disease has mapped how gene activity changes across more than 50 cell types in the gut. The study provides an open resource of the genes that characterise each cell type and those whose activity shifts in disease, uncovering new molecular and cellular signatures of immune activity in the gut lining.</p>
152
153<p>Researc... 
154  </p>
155  
156  <p class="card-title">
157    <a href="/news/ibdverse-krzak-june2026.html" class="btn btn-primary">Read more</a>
158  </p>
159  
160
161</div>  
162              </div>
163            </div>
164            <div class="col-lg-12">
165              <hr class="my-5" />
166            </div>
167          </div>
168        
169          <div class="row">
170            <div class="col-lg-12">
171              <div class="row">
172                <div class="col-lg-6">
173  
174  <a href="/" target="_blank">
175    <img src="/assets/img/alegbeharris.png" class="img-fluid" alt="Graphic describing the project"/>
176  </a>
177  
178</div>
179<div class="col-lg-6">
180  <h4>Study of millions of cells reveals new way to understand genetic risk of disease</h4>
181  <p class="mt-3">
182    3 June 2026
183  </p>
184  <p>
185    <p>Scientists have created the most detailed cell map to date showing how genetic variation influences inflammatory bowel disease (IBD), revealing the specific cells and genes that drive the disease.</p>
186
187<p>Published today (3 June) in Nature, the research carried out at the Wellcome Sanger Institute, Open Targets, and Cambridge University Hospitals NHS Foundation Trust (CUH), identifies the key genetic and cellular drivers of IBD risk and demonstrates the power of single-cell approaches to u... 
188  </p>
189  
190  <p class="card-title">
191    <a href="/news/ibdverse-alegbeharris-june-2026.html" class="btn btn-primary">Read more</a>
192  </p>
193  
194
195</div>  
196              </div>
197            </div>
198            <div class="col-lg-12">
199              <hr class="my-5" />
200            </div>
201          </div>
202        
203          <div class="row">
204            <div class="col-lg-12">
205              <div class="row">
206                <div class="col-lg-6">
207  
208  <a href="https://www.sanger.ac.uk/news_item/immunotherapy-success-could-be-predicted-with-new-biomarkers//" target="_blank">
209    <img src="/assets/img/cancer-biomarkers-watterson-jan26.png" class="img-fluid" alt="A tumoroid, colon cancer cells grown in 3D"/>
210  </a>
211  
212</div>
213<div class="col-lg-6">
214  <h4>Immunotherapy success could be predicted with new biomarkers</h4>
215  <p class="mt-3">
216    20 January 2026
217  </p>
218  <p>
219    <p>The deletion of two cancer genes, CHD1 and MAP3K7, improves how well tumours respond to cancer immunotherapy and could be used as biomarkers to help predict which patients are most likely to benefit from treatment, new research shows.</p>
220
221<p>Researchers at the Wellcome Sanger Institute, Open Targets, Netherlands Cancer Institute and their collaborators used a powerful gene-editing tool called CRISPR in a novel approach that cultured tumour cells together with immune cells from the same in... 
222  </p>
223  
224  <p class="card-title">
225    <a href="https://www.sanger.ac.uk/news_item/immunotherapy-success-could-be-predicted-with-new-biomarkers/" class="btn btn-primary" target="_blank">Read more</a>
226  </p>
227  
228
229</div>  
230              </div>
231            </div>
232            <div class="col-lg-12">
233              <hr class="my-5" />
234            </div>
235          </div>
236        
237          <div class="row">
238            <div class="col-lg-12">
239              <div class="row">
240                <div class="col-lg-6">
241  
242  <a href="https://www.ebi.ac.uk/about/news/announcements/new-data-initiative-launched-to-accelerate-discovery-and-personalised-care-for-mental-health-conditions//" target="_blank">
243    <img src="/assets/img/OPP-funding-announcement.png" class="img-fluid" alt="Funding announcement"/>
244  </a>
245  
246</div>
247<div class="col-lg-6">
248  <h4>New data initiative accelerates discovery and personalised care for mental health conditions</h4>
249  <p class="mt-3">
250    25 November 2025
251  </p>
252  <p>
253    <p>EMBL-EBI receives UKRI Medical Research Council (MRC) and National Institute for Health and Care Research (NIHR) funding for enhancing and translating mental-health omics data into the Open Targets Platform.</p>
254 
255  </p>
256  
257  <p class="card-title">
258    <a href="https://www.ebi.ac.uk/about/news/announcements/new-data-initiative-launched-to-accelerate-discovery-and-personalised-care-for-mental-health-conditions/" class="btn btn-primary" target="_blank">Read more</a>
259  </p>
260  
261
262</div>  
263              </div>
264            </div>
265            <div class="col-lg-12">
266              <hr class="my-5" />
267            </div>
268          </div>
269        
270          <div class="row">
271            <div class="col-lg-12">
272              <div class="row">
273                <div class="col-lg-6">
274  
275  <a href="/" target="_blank">
276    <img src="/assets/img/tumour_organoid_WellcomeSangerInstitute.png" class="img-fluid" alt="A tumoroid, colon cancer 
276cells grown in 3D"/>
277  </a>
278  
279</div>
280<div class="col-lg-6">
281  <h4>Cancer drug resistance causes and categories identified</h4>
282  <p class="mt-3">
283    18 October 2024
284  </p>
285  <p>
286    <p><strong>Researchers have mapped the genetic landscape of cancer drug resistance, uncovering that DNA changes can be grouped into four main categories and highlighting possible new therapeutic targets.</strong></p>
287
288<p><br /></p>
289
290<p>All cancer mutations that cause drug resistance fall into one of four categories. New research has detailed each type, helping to uncover targets for drug development and identify potential effective second-line therapies.</p>
291
292<p>In a new large-scale study, re... 
293  </p>
294  
295  <p class="card-title">
296    <a href="/news/cancer-drug-resistance-18-october-2024.html" class="btn btn-primary">Read more</a>
297  </p>
298  
299
300</div>  
301              </div>
302            </div>
303            <div class="col-lg-12">
304              <hr class="my-5" />
305            </div>
306          </div>
307        
308          <div class="row">
309            <div class="col-lg-12">
310              <div class="row">
311                <div class="col-lg-6">
312  
313  <a href="/" target="_blank">
314    <img src="/assets/img/clinical-trial-stop-reasons-Jul24.png" class="img-fluid" alt="Graphic showing predicted trial stop reasons in rows with counts of trials per start year, clinical phase or therapeutic area shown by the color in each cell. The outcome groupings of the stopped reasons are shown using the color next to the stopped reason label."/>
315  </a>
316  
317</div>
318<div class="col-lg-6">
319  <h4>Why clinical trials stop: the role of genetics</h4>
320  <p class="mt-3">
321    29 July 2024
322  </p>
323  <p>
324    <p><strong>Using machine learning to analyse the genetic factors behind early clinical trial termination, researchers find a link between genetic evidence and trial outcome.</strong></p>
325
326<p><br /></p>
327
328<p>Failure is the most likely outcome of a clinical trial. Learning from these failures by understanding which factors maximise the chances of a successful trial would help improve the drug discovery process. However, accessing information about failed clinical trials is difficult since the dr... 
329  </p>
330  
331  <p class="card-title">
332    <a href="/news/clinical-trial-stop-reasons-Jul24.html" class="btn btn-primary">Read more</a>
333  </p>
334  
335
336</div>  
337              </div>
338            </div>
339            <div class="col-lg-12">
340              <hr class="my-5" />
341            </div>
342          </div>
343        
344          <div class="row">
345            <div class="col-lg-12">
346              <div class="row">
347                <div class="col-lg-6">
348  
349  <a href="/" target="_blank">
350    <img src="/assets/img/vallier-liver-regeneration.png" class="img-fluid" alt="Liver hepatocytes"/>
351  </a>
352  
353</div>
354<div class="col-lg-6">
355  <h4>Researchers decipher mechanisms of liver regeneration</h4>
356  <p class="mt-3">
357    23 May 2024
358  </p>
359  <p>
360    <p><strong>Scientists from the Berlin Institute of Health at Charité (BIH) and Open Targets together with colleagues from the University of Cambridge, and Addenbrooke’s Hospital in Cambridge, UK, uncovered mechanisms driving regeneration of the liver during chronic liver disease. This regenerative process allows the liver to repair itself when chronically injured but could also result in progression toward cancer. The researchers were able to demonstrate this first by performing single-cell a... 
361  </p>
362  
363  <p class="card-title">
364    <a href="/news/mechanisms-of-liver-regeneration-vallier-may-2024.html" class="btn btn-primary">Read more</a>
365  </p>
366  
367
368</div>  
369              </div>
370            </div>
371            <div class="col-lg-12">
372              <hr class="my-5" />
373            </div>
374          </div>
375        
376          <div class="row">
377            <div class="col-lg-12">
378              <div class="row">
379                <div class="col-lg-6">
380  
381  <a href="/" target="_blank">
382    <img src="/assets/img/openibd-press-release.png" class="img-fluid" alt="Open-IBD logo"/>
383  </a>
384  
385</div>
386<div class="col-lg-6">
387  <h4>Ambitious inflammatory bowel disease study aims to uncover disease biomarkers for personalised medicine</h4>
388  <p class="mt-3">
389    17 May 2024
390  </p>
391  <p>
392    <p><strong>A unique study into IBD will bring together genomics and immunology experts, gastroenterologists, and patients from across the UK to i
392dentify new and personalised ways to predict, monitor, and treat Crohn’s disease and ulcerative colitis.</strong></p>
393
394<p>A new one-of-a-kind study into inflammatory bowel disease (IBD) is bringing together research institutions, hospitals, pharmaceutical partners, and patients to uncover what drives IBD onset and severity, identifying biomarkers to ... 
395  </p>
396  
397  <p class="card-title">
398    <a href="/news/open-ibd-may-24.html" class="btn btn-primary">Read more</a>
399  </p>
400  
401
402</div>  
403              </div>
404            </div>
405            <div class="col-lg-12">
406              <hr class="my-5" />
407            </div>
408          </div>
409        
410          <div class="row">
411            <div class="col-lg-12">
412              <div class="row">
413                <div class="col-lg-6">
414  
415  <a href="/" target="_blank">
416    <img src="/assets/img/msd-press-release.png" class="img-fluid" alt="MSD Logo"/>
417  </a>
418  
419</div>
420<div class="col-lg-6">
421  <h4>MSD joins the Open Targets consortium</h4>
422  <p class="mt-3">
423    30 April 2024
424  </p>
425  <p>
426    <p>Open Targets, a public-private partnership dedicated to pre-competitive drug discovery research, today announced MSD, the tradename of Merck &amp; Co., Inc., Rahway, N.J., USA, as the latest partner to join the consortium. Open Targets aims to accelerate the development of safe and effective medicines by leveraging cutting-edge technologies to identify, prioritise, and validate potential drug targets. MSD’s expertise in drug discovery will complement the strengths of the current partners: ... 
427  </p>
428  
429  <p class="card-title">
430    <a href="/news/msd-joins-Open-Targets-Apr-2024.html" class="btn btn-primary">Read more</a>
431  </p>
432  
433
434</div>  
435              </div>
436            </div>
437            <div class="col-lg-12">
438              <hr class="my-5" />
439            </div>
440          </div>
441        
442          <div class="row">
443            <div class="col-lg-12">
444              <div class="row">
445                <div class="col-lg-6">
446  
447  <a href="https://www.sanger.ac.uk/news_item/new-screening-tool-to-explore-mechanisms-behind-cancer-autoimmunity-and-neurodegeneration//" target="_blank">
448    <img src="/assets/img/scSNV-seq-Feb24-Greg-Moss.png" class="img-fluid" alt="A row of sequencing machines"/>
449  </a>
450  
451</div>
452<div class="col-lg-6">
453  <h4>New screening tool to explore mechanisms behind cancer, autoimmunity and neurodegeneration</h4>
454  <p class="mt-3">
455    27 February 2024
456  </p>
457  <p>
458    <p>Mechanisms driving diseases such as cancer, autoimmunity, Alzheimer’s and Parkinson’s could be uncovered using a new integrated single-cell approach to cellular genetic screening.</p>
459 
460  </p>
461  
462  <p class="card-title">
463    <a href="https://www.sanger.ac.uk/news_item/new-screening-tool-to-explore-mechanisms-behind-cancer-autoimmunity-and-neurodegeneration/" class="btn btn-primary" target="_blank">Read more</a>
464  </p>
465  
466
467</div>  
468              </div>
469            </div>
470            <div class="col-lg-12">
471              <hr class="my-5" />
472            </div>
473          </div>
474        
475          <div class="row">
476            <div class="col-lg-12">
477              <div class="row">
478                <div class="col-lg-6">
479  
480  <a href="/" target="_blank">
481    <img src="/assets/img/second-depmap-cover-nci.png" class="img-fluid" alt="Laboratory Researcher setting up genetic samples and primers for polymerase chain reaction."/>
482  </a>
483  
484</div>
485<div class="col-lg-6">
486  <h4>Cancer drug discovery accelerated as hundreds of overlooked targets prioritised</h4>
487  <p class="mt-3">
488    11 January 2024
489  </p>
490  <p>
491    <p><i>The second generation of the Cancer Dependency Map uncovers 370 priority drug targets, with strong links to specific cancer types.</i></p>
492
493<p>A new, systematic analysis of cancer cells identifies 370 candidate priority drug targets across 27 cancer types, including breast, lung and ovarian cancers.</p>
494
495<p>By looking at multiple layers of functional and genomic information, researchers were able to create an unbiased, panoramic view of what enables cancer cells to grow and survive. The... 
496  </p>
497  
498  <p class="card-title">
499    <a href="/news/second-generation-depmap-11-january-2024.html" class="btn btn-primary">Read more</a>
500  </p>
501  
502
503</div>  
504              </div>
505            </div>
506            <div class="col-lg-12">
507              <hr class="my-5" />
508            </div>
509          </div>
510        
511          <div class="row">
512            <div class="col-lg-12">
513              <div class="row">
514                <div class="col-lg-6">
515  
516  <a href="/" target="_blank">
517    <img src="/assets/img/HULCOOP_David_new_director_2023.png" class="img-fluid" alt="A man in a blue shirt is standing on the balcony of an office building made of metal and glass. He is posing and smiling at the camera, left hand in his pocket and right hand resting on the balcony railing. Surrounding trees can be seen in the background and reflected in the building."/>
518  </a>
519  
520</div>
521<div class="col-lg-6">
522  <h4>David Hulcoop appointed Open Targets Director</h4>
523  <p class="mt-3">
524    5 July 2023
525  </p>
526  <p>
527    <p><i>July 5, Cambridge</i> — Open Targets has appointed David Hulcoop as its new Executive Director, following the retirement of Ian Dunham. Hulcoop will build from the programme’s existing capabilities to maximise Open Targets impact on drug discovery decision making.</p>
528
529<p>Open Targets, a public-private partnership founded in 2014, aims to use the information generated by genome sequencing and genetics studies to systematically improve the identification and prioritisation of drug target... 
530  </p>
531  
532  <p class="card-title">
533    <a href="/news/david-hulcoop-director-july-2023.html" class="btn btn-primary">Read more</a>
534  </p>
535  
536
537</div>  
538              </div>
539            </div>
540            <div class="col-lg-12">
541              <hr class="my-5" />
542            </div>
543          </div>
544        
545          <div class="row">
546            <div class="col-lg-12">
547              <div class="row">
548                <div class="col-lg-6">
549  
550  <a href="/" target="_blank">
551    <img src="/assets/img/Pleiotropy_Karen_Arnott.png" class="img-fluid" alt="A stylized network of interconnected circles"/>
552  </a>
553  
554</div>
555<div class="col-lg-6">
556  <h4>Open Targets project creates a human interactome to prioritise drug discovery</h4>
557  <p class="mt-3">
558    23 February 2023
559  </p>
560  <p>
561    <p>Scientists at Open Targets, EMBL’s European Bioinformatics Institute (EMBL-EBI), and GSK are revealing the shared basis of diseases using a map of interacting human proteins. By helping to understand how biological processes affect human traits and diseases, this work will prioritise new targets for drug discovery and identify drug repurposing opportunities.</p>
562
563<p>Proteins are molecules that do most of the work in our cells and are made following blueprints encoded in genes. They are ess... 
564  </p>
565  
566  <p class="card-title">
567    <a href="/news/human-interactome-23-february-2023.html" class="btn btn-primary">Read more</a>
568  </p>
569  
570
571</div>  
572              </div>
573            </div>
574            <div class="col-lg-12">
575              <hr class="my-5" />
576            </div>
577          </div>
578        
579          <div class="row">
580            <div class="col-lg-12">
581              <div class="row">
582                <div class="col-lg-6">
583  
584  <a href="/" target="_blank">
585    <img src="/assets/img/bowel-cancer-national-cancer-institute.png" class="img-fluid" alt="Human colorectal cancer cells stained purple, blue, and green under a microscope."/>
586  </a>
587  
588</div>
589<div class="col-lg-6">
590  <h4>Bowel cancer mutations that impact immunotherapy identified</h4>
591  <p class="mt-3">
592    19 January 2023
593  </p>
594  <p>
595    <p><strong>Researchers used CRISPR and mini tumours to discover more about how cancer develops and responds to the body’s immune response.</strong></p>
596
597<p>A new library documenting hundreds of mutations can help to explain why some cancers don’t respond to immunotherapies, and highlights potential pathways that could be drug targets in the future.</p>
598
599<p>The researchers, from the Wellcome Sanger Institute, Open Targets, and collaborators, used CRISPR gene editing technology and mini tumours... 
600  </p>
601  
602  <p class="card-title">
603    <a href="/news/bowel-cancer-mutations-that-impact-immunotherapy-identified-19-january-2023.html" class="btn btn-primary">Read more</a>
604  </p>
605  
606
607</div>  
608              </div>
609            </div>
610            <div class="col-lg-12">
611              <hr class="my-5" />
612            </div>
613          </div>
614        
615          <div class="row">
616            <div class="col-lg-12">
617              <div class="row">
618                <div class="col-lg-6">
619  
620  <a href="/" target="_blank">
621    <img src="/assets/img/OT_logo_400x800.png" class="img-fluid" alt="Open Targets logo"/>
622  </a>
623  
624</div>
625<div class="col-lg-6">
626  <h4>Open Targets consortium welcomes Genentech as newest member</h4>
627  <p class="mt-3">
628    14 November 2022
629  </p>
630  <p>
631    <p>Open Targets announced today that Genentech, a member of the Roche Group, has joined the consortium, which identifies, prioritises, and validates drug targets to accelerate the development of safe and effective medicines. The second company to 
631join the industry-academic partnership this year, Genentech will collaborate with other consortium members including EMBL’s European Bioinformatics Institute (EMBL-EBI), the Wellcome Sanger Institute, GSK, Bristol Myers Squibb, Sanofi, and Pfizer.</p... 
632  </p>
633  
634  <p class="card-title">
635    <a href="/news/genentech-joins-Open-Targets-Nov-2022.html" class="btn btn-primary">Read more</a>
636  </p>
637  
638
639</div>  
640              </div>
641            </div>
642            <div class="col-lg-12">
643              <hr class="my-5" />
644            </div>
645          </div>
646        
647          <div class="row">
648            <div class="col-lg-12">
649              <div class="row">
650                <div class="col-lg-6">
651  
652  <a href="/" target="_blank">
653    <img src="/assets/img/soskic-cano-gamez-natgen-may22.png" class="img-fluid" alt="DNA spiral formed by pale blue dots on a dark background"/>
654  </a>
655  
656</div>
657<div class="col-lg-6">
658  <h4>Study tracking T-cell activation over time boosts search for immune disease treatments</h4>
659  <p class="mt-3">
660    26 May 2022
661  </p>
662  <p>
663    <p>In a first-of-its-kind experiment, researchers have identified links between 127 genes and immune diseases, providing newfound insights into the sequence and timing of gene activity during the activation of T cells, a key process in regulating the body’s immune response.</p>
664
665<p>The study, led by researchers from Open Targets, the Wellcome Sanger Institute and GSK, is published today (26 May 2022) in Nature Genetics. The result of a 3 year research effort, it is the first to show that nume... 
666  </p>
667  
668  <p class="card-title">
669    <a href="/news/T-cell-activation-dynamics-NatGen-May22.html" class="btn btn-primary">Read more</a>
670  </p>
671  
672
673</div>  
674              </div>
675            </div>
676            <div class="col-lg-12">
677              <hr class="my-5" />
678            </div>
679          </div>
680        
681          <div class="row">
682            <div class="col-lg-12">
683              <div class="row">
684                <div class="col-lg-6">
685  
686  <a href="/" target="_blank">
687    <img src="/assets/img/Pfizer-press-release.png" class="img-fluid" alt="Pfizer logo on a white background"/>
688  </a>
689  
690</div>
691<div class="col-lg-6">
692  <h4>Pfizer joins the Open Targets consortium</h4>
693  <p class="mt-3">
694    14 February 2022
695  </p>
696  <p>
697    <p>Open Targets, a consortium focused on drug target identification, prioritisation, and validation, announced today that Pfizer has joined as a partner. Pfizer will contribute its unique expertise in oncology, immunology, and metabolic disorders as part of the innovative public-private partnership which uses human genetics and genomics data with the aim of improving the success rate for developing new medicines. This complements the strengths of the five current partners: EMBL’s European Bio... 
698  </p>
699  
700  <p class="card-title">
701    <a href="/news/pfizer-press-release-Feb-2022.html" class="btn btn-primary">Read more</a>
702  </p>
703  
704
705</div>  
706              </div>
707            </div>
708            <div class="col-lg-12">
709              <hr class="my-5" />
710            </div>
711          </div>
712        
713          <div class="row">
714            <div class="col-lg-12">
715              <div class="row">
716                <div class="col-lg-6">
717  
718  <a href="https://www.nature.com/articles/s41588-021-00945-5/" target="_blank">
719    <img src="/assets/img/l2g-pipeline-news-item.png" class="img-fluid" alt="Screenshot of steps involved in Open Targets Locus2Gene assignment pipeline"/>
720  </a>
721  
722</div>
723<div class="col-lg-6">
724  <h4>Locus-to-Gene method published in Nature Genetics</h4>
725  <p class="mt-3">
726    28 October 2021
727  </p>
728  <p>
729    <p>Our locus-to-gene (L2G) machine learning scoring method was published in Nature Genetics (<a href="https://www.biorxiv.org/content/10.1101/2020.09.16.299271v2" target="_blank">the preprint is also available</a>). The L2G score reflects the likelihood that a gene is causal for the trait in question, allowing genes at trait-associated loci to be ranked by the relative strength of their evidence. It has been included in the Genetics portal since version 4.</p>
730 
731  </p>
732  
733  <p class="card-title">
734    <a href="https://www.nature.com/articles/s41588-021-00945-5" class="btn btn-primary" target="_blank">Read more</a>
735  </p>
736  
737
738</div>  
739              </div>
740            </div>
741            <div class="col-lg-12">
742              <hr class="my-5" />
743            </div>
744          </div>
745        
746          <div class="row">
747            <div class="col-lg-12">
748              <div class="row">
749                <div class="col-lg-6">
750  
751  <a href="https://blog.opentargets.org/open-targets-genetics-version-5//" target="_blank">
752    <img src="/assets/img/Genetics_Portal_v5_release_PheWAS_plot.png" class="img-fluid" alt="Screenshot of Open Targets Genetics PheWAS plot showing dropdown options"/>
753  </a>
754  
755</div>
756<div class="col-lg-6">
757  <h4>Open Targets releases new version of the Genetics Portal with FinnGen data</h4>
758  <p class="mt-3">
759    30 June 2021
760  </p>
761  <p>
762    <p>
762In our latest <a href="https://genetics.opentargets.org/" target="_blank">Genetics Portal<a> release, we have <b>integrated over 2,700 study endpoints from FinnGen</b>, a public-private collaboration to identify genotype-phenotype correlations in the Finnish population. We have also <b>integrated over 11,800 new studies</b> from GWAS Catalog.</a></a></p>
763 
764  </p>
765  
766  <p class="card-title">
767    <a href="https://blog.opentargets.org/open-targets-genetics-version-5/" class="btn btn-primary" target="_blank">Read more</a>
768  </p>
769  
770
771</div>  
772              </div>
773            </div>
774            <div class="col-lg-12">
775              <hr class="my-5" />
776            </div>
777          </div>
778        
779          <div class="row">
780            <div class="col-lg-12">
781              <div class="row">
782                <div class="col-lg-6">
783  
784  <a href="https://blog.opentargets.org/2020/07/29/covid-19-target-prioritisation-tool-released//" target="_blank">
785    <img src="/assets/img/covid-19-portal-screenshot.png" class="img-fluid" alt="Screenshot of the Open Targets COVID19 Target Prioritisation tool showing a list of targets and key attributes for drug discovery"/>
786  </a>
787  
788</div>
789<div class="col-lg-6">
790  <h4>Open Targets releases a COVID-19 Target Prioritisation Tool</h4>
791  <p class="mt-3">
792    29 July 2020
793  </p>
794  <p>
795    <p>Open Targets is excited to announce the release of our <a href="http://covid19.opentargets.org/" target="_blank">COVID-19 Target Prioritisation Tool</a>, an interactive, open source web portal that integrates a number of key public datasets and publications to facilitate systematic exploration of host and viral targets as well as potential treatments for 
796<a href="https://platform.opentargets.org/disease/MONDO_0100096" target="_blank">COVID-19</a>.</p>
797 
798  </p>
799  
800  <p class="card-title">
801    <a href="https://blog.opentargets.org/2020/07/29/covid-19-target-prioritisation-tool-released/" class="btn btn-primary" target="_blank">Read more</a>
802  </p>
803  
804
805</div>  
806              </div>
807            </div>
808            <div class="col-lg-12">
809              <hr class="my-5" />
810            </div>
811          </div>
812        
813          <div class="row">
814            <div class="col-lg-12">
815              <div class="row">
816                <div class="col-lg-6">
817  
818    <img src="/assets/img/open_targets_logo_news_item_placeholder.png" class="img-fluid" alt="Open Targets Helix logo and wordmark"/>
819  
820</div>
821<div class="col-lg-6">
822  <h4>Gosia Trynka awarded 2020 Leena Peltonen Prize</h4>
823  <p class="mt-3">
824    6 June 2020
825  </p>
826  <p>
827    <p>Open Targets is excited to announce that <a href="https://www.sanger.ac.uk/person/trynka-gosia//">Gosia Trynka</a>, 
828our Experimental Science Director, has been awarded the 2020 Leena Peltonen prize by 
829the European Society for Human Genetics (ESHG).</p>
830
831<p>The prize is given every two years to an outstanding young researcher in the field of human genetics and it 
832honours the memory of <a href="https://www.sanger.ac.uk/news_item/2010-03-11-professor-leena-peltonen-palotie-1952-2010/">Dr. ... 
833  </p>
834  
835  <p class="card-title">
836    <a href="/assets/docs/Trynka_Peltonen_prize_announcement.pdf" class="btn btn-primary" target="_blank">Read more</a>
837  </p>
838  
839
840</div>  
841              </div>
842            </div>
843            <div class="col-lg-12">
844              <hr class="my-5" />
845            </div>
846          </div>
847         
848    </div>
849  </div>
850</section>
851
852    <footer class="py-5 my-5 text-white" style="background-color: #5a5f5f">
853  <div class="container text-center text-md-left">
854    <div class="row">
855      <div class="col-md-6 mt-md-0 mt-3">
856        <h5 class="text-uppercase">Contact</h5>
857        <p>
858          To contact the Open Targets team, please email us at
859          <a class="text-white" href="mailto:[email protected]"
860            >[email protected]</a
861          >
862        </p>
863        <p><a class="text-white" href="https://www.ebi.ac.uk/data-protection/privacy-notice/embl-ebi-public-website/">Privacy Notice</a></p>
864        <h5 class="text-uppercase">Follow us</h5>
865        <ul class="list-unstyled list-inline">
866          <li class="list-inline-item">
867            <a
868              class="text-white"
869              href="https://www.linkedin.com/company/open-targets"
870              target="_blank"
871            >
872              <i class="fa fa-brands fa-2x fa-linkedin"></i>
873            </a>
874          </li>
875          <li class="list-inline-item">
876            <a
877              class="text-white"
878              href="https://github.com/opentargets"
879              target="_blank"
880            >
881              <i class="fa-brands fa-2x fa-github"></i>
882            </a>
883          </li>
884          <li class="list-inline-item">
885            <a
886              class="text-white"
887              href="https://bsky.app/profile/opentargets.org"
888              target="_blank"
889            >
890              <i class="fa fa-brands fa-2x fa-bluesky"></i>
891            </a>
892          </li>
893          <li class="list-inline-item">
894            <a
895              class="text-white"
896              href="https://twitter.com/opentargets"
897              target="_blank"
898            >
899              <i class="fa fa-brands fa-2x fa-x-twitter"></i>
900            </a>
901          </li>
902        </ul>
903        <a href="https://www.netlify.com">
904          <img
905            src="https://www.netlify.com/img/global/badges/netlify-light.svg"
906            alt="Deploys by Netlify"
907          />
908        </a>
909      </div>
910      <!-- Grid column -->
911
912      <hr class="clearfix w-100 d-md-none pb-3" />
913
914      <!-- Grid column -->
915      <div class="col-md-3 mb-md-0 mb-3">
916        <!-- Links -->
917        <h5 class="text-uppercase">Partners</h5>
918
919        <ul class="list-unstyled">
920          <li>
921            <a class="text-white" href="https://www.ebi.ac.uk/" target="_blank"
922              >
922European Bioinformatics Institute</a
923            >
924          </li>
925          <li>
926            <a class="text-white" href="https://www.gene.com/" target="_blank"
927              >Genentech</a
928            >
929          </li>
930          <li>
931            <a class="text-white" href="https://www.gsk.com/" target="_blank"
932              >GSK</a
933            >
934          </li>
935          <li>
936            <a class="text-white" href="https://www.msd.com/" target="_blank"
937              >MSD</a
938            >
939          </li>
940          <li>
941            <a class="text-white" href="https://www.pfizer.com/" target="_blank"
942              >Pfizer</a
943            >
944          </li>
945          <li>
946            <a class="text-white" href="https://www.sanofi.com/" target="_blank"
947              >Sanofi</a
948            >
949          </li>
950          <li>
951            <a
952              class="text-white"
953              href="https://www.sanger.ac.uk/"
954              target="_blank"
955              >Wellcome Sanger Institute</a
956            >
957          </li>
958        </ul>
959      </div>
960      <hr class="clearfix w-100 d-md-none pb-3" />
961      <div class="col-md-3 mb-md-0 mb-3">
962        <h5 class="text-uppercase">Open Targets</h5>
963        <ul class="list-unstyled">
964          <li>
965            <a class="text-white" href="/science">Science</a>
966          </li>
967          <li>
968            <a class="text-white" href="/people">Team</a>
969          </li>
970          <li>
971            <a class="text-white" href="/publications">Publications</a>
972          </li>
973          <li>
974            <a class="text-white" href="/resources">Informatics tools</a>
975          </li>
976          <li>
977            <a class="text-white" href="/jobs">Jobs</a>
978          </li>
979          <li>
980            <a
981              class="text-white"
982              href="https://community.opentargets.org/"
983              target="_blank"
984              >Community</a
985            >
986          </li>
987          <li>
988            <a
989              class="text-white"
990              href="https://blog.opentargets.org/"
991              target="_blank"
992              >Blog</a
993            >
994          </li>
995          <li>
996            <a class="text-white" href="/contact">Contact</a>
997          </li>
998        </ul>
999      </div>
1000    </div>
1001  </div>
1002
1003  <div class="text-center py-3">
1004    Copyright © 2017-2025 Open Targets. All rights reserved.
1005  </div>
1006</footer>
1007
1008    
1008<script src="https://code.jquery.com/jquery-3.2.1.slim.min.js" integrity="sha384-KJ3o2DKtIkvYIK3UENzmM7KCkRr/rE9/Qpg6aAZGJwFDMVNA/GpGFF93hXpG5KkN" crossorigin="anonymous"></script>
1008
1009    
1009<script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.12.9/umd/popper.min.js" integrity="sha384-ApNbgh9B+Y1QKtv3Rn7W3mgPxhU9K/ScQsAP7hUibX39j7fakFPskvXusvfa0b4Q" crossorigin="anonymous"></script>
1009
1010    
1010<script src="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0/js/bootstrap.min.js" integrity="sha384-JZR6Spejh4U02d8jOt6vLEHfe/JQGiRRSQQxSfFWpi1MquVdAyjUar5+76PVCmYl" crossorigin="anonymous"></script>
1010
1011    
1012  </body>
1013</html>

Line numbers count LF bytes from the start of the resource, as the search results do. Vendor segments are library code the classifier recognised; they are stored but not indexed. Bytes are shown as Latin1 characters, one per byte.